drugset / Trial / NCT01142856

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856

Phase 1 Completed 1 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.

Timeline

Start
2010-06
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells Intrathecal